Linked Life Data

11706098

Source:http://linkedlifedata.com/resource/pubmed/id/11706098

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2001-11-13
pubmed:abstractText
Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0028-3878
pubmed:author
pubmed:issnType
Print
pubmed:day
13
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1595-602
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients.
pubmed:affiliation
Oregon Stroke Center, Oregon Health Sciences University, Portland, OR 97201, USA. Clarkw@ohsu.edu
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III